Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience

Urbino, Irene; Secreto, Carolina; Apolito, Vincenzo; Olivi, Matteo; Arrigo, Giulia; Boscaro, Eleonora; Catania, Federica Maria; D’Ardia, Stefano; Frairia, Chiara; Giai, Valentina; Freilone, Roberto; Bruno, Benedetto; Lanzarone, Giuseppe; Giaccone, Luisa; Busca, Alessandro; Dellacasa, Chiara Maria; Ferrero, Dario; Audisio, Ernesta; Cerrano, Marco

doi:10.1016/j.leukres.2023.107421

Leukemia Research

2024

DOI: 10.1016/j.leukres.2023.107421

|View full text |Cite

Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience

Irene Urbino,

Carolina Secreto,

Vincenzo Apolito

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia

Bruzzese,

Vigna,

Martino

et al. 2024

Expert Review of Hematology

View full text Add to dashboard Cite

The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia

Bruzzese,

Vigna,

Martino

et al. 2024

Expert Review of Hematology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience

Cited by 1 publication

References 20 publications

The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia

The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia

Contact Info

Product

Resources

About